comprehensive -WSS

comprehensive

author：explore 2025-09-29 04:51:19 - browse：78

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Ohio train derailment: Experts on toxic chemical risks

WSS

5 ways to address the shortage of health care workers

Why Eli Lilly’s earnings didn’t quite live up to the hype

Congress must protect the remaining independent doctors

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

hotspot

comprehensive

focus

Peter Hotez and the public health issue of online harassment

STAT Boddities: What happens to the brain when we get scared?

The high cost of giving birth even with insurance

Eli Lilly reports tirzepatide MASH success during Q4 earnings

What does generative AI mean for health care? We asked experts

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Continuity nursing helped my family in our darkest PICU moments

Are embryos people? Reproductive medicine's future depends on the answer

United colonoscopy coverage change 'may cost lives,' doctors say

CDC panel: People 65 and older should get a Covid spring booster shot

hotspot

Cholera vaccine supplies dangerously low, outbreaks surging

Abbott's new heart device gets FDA advisory panel nod

Change Healthcare cyberattack shows risk of industry consolidation

Change Healthcare cyberattack shows risk of industry consolidation

Latigo launches with $135 million for Vertex

Report cites 'urgent' need to recruit more diverse clinical trial participants

hotspot

explore

focus

entertainment